Harmony biosciences acknowledges u.s. food & drug administration (fda) action denying the citizen petition for wakix® (pitolsiant)

Fda confirms the favorable benefit-risk profile of wakix harmony biosciences focused on continuing to advance its pipeline assets across three rare cns franchises; anticipates at least one new product or indication launch annually over the next five years plymouth meeting, pa. , june 25, 2024 /prnewswire/ -- harmony biosciences holdings, inc. (nasdaq: hrmy), today announced that the u.s. food and drug administration denied the citizen petition filed by a short seller claiming that wakix is not safe and effective for the treatment of excessive daytime sleepiness (eds) and cataplexy in adults with narcolepsy.
DRUG Ratings Summary
DRUG Quant Ranking